http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022028007-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6152fe6194bd8ab9a732b7615fc003c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04
filingDate 2021-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3413c8254ef89d8cd8e3faaaba7d638a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e0f3818a585c7684ac437ad02bf9e8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fda44fd3839869d1ad50def0df20c35d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85eecaf4fc449b7e53de4edd564d6272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7a4bee0a67c617fdb0162b91f4ac027
publicationDate 2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022028007-A1
titleOfInvention Intermediate for preparing edoxaban free base, preparation method therefor, and application thereof
abstract The present disclosure relates to an intermediate for preparing edoxaban free base, a preparation method therefor and an application thereof. The preparation method for the intermediate comprises the following steps: in an organic solvent and under an action of an alkali, subjecting 5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxylic acid or salts thereof and acyl chloride to a reaction. The intermediate can be used to synthesize edoxaban free base in a low-cost, green, environmentally friendly, simple, efficient and safe way, and the drug safety of the edoxaban product obtained can be enhanced. The preparation of edoxaban free base comprises the following steps: in an organic solvent, subjecting the salts of compound (II) and compound (IV) to a reaction; or, in an organic solvent and under an action of an alkali, subjecting the salts of compound (II) and compound (IV) to a reaction. The compound (II), the edoxaban free base and the compound (IV) have the following structures.
priorityDate 2020-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106866452-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014081047-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014157612-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104761571-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105753888-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105198776-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107721866-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412241206
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467963183
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467963142
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163634551
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465261331
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID59676986

Total number of triples: 29.